MAP2K7 and plexiform neurofibroma: The first-of-its-kind treatment is the U.S. Food and Drug Administration-approved MEK inhibitor selumetinib that shrinks tumor volume and reduces neurofibroma-related pain (Casey et al., 2021; Gross et al., 2020).